N-((4a′R,11b′R)-2′-amino-11b′-methyl-4′,4′-dioxido-4a′,5′,6′,11b′-tetrahydrospiro[cyclobutane-1,3′-pyrido[3′,2′:6,7]oxepino[4,5-b][1,4]thiazin]-10′-yl)-5-cyano-2-pyridinecarboxamide | 1620978-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-((4a′R,11b′R)-2′-amino-11b′-methyl-4′,4′-dioxido-4a′,5′,6′,11b′-tetrahydrospiro[cyclobutane-1,3′-pyrido[3′,2′:6,7]oxepino[4,5-b][1,4]thiazin]-10′-yl)-5-cyano-2-pyridinecarboxamide
• 英文别名: N-((4a'R,11b'R)-2'-amino-11b'-methyl-4',4'-dioxido-4a',5',6',11b'-tetrahydrospiro[cyclobutane-1,3'-pyrido[3',2':6,7]oxepino[4,5-b][1,4]thiazin]-10'-yl)-5-cyanopicolinamide；N-[(2R,7R)-4-amino-2-methyl-6,6-dioxospiro[10-oxa-6λ6-thia-3,12-diazatricyclo[9.4.0.02,7]pentadeca-1(11),3,12,14-tetraene-5,1'-cyclobutane]-14-yl]-5-cyanopyridine-2-carboxamide
• CAS: 1620978-95-1
• 化学式: C₂₂H₂₂N₆O₄S
• 分子量: 466.52
• InChiKey: JDBKXMXHMMUAIM-DYESRHJHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  33
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  169
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  tert-butyl ((4a'R,11b'R)-10'-(5-cyanopicolinamido)-11b'-methyl-4',4'-dioxido-4a',5',6',11b'-tetrahydrospiro[cyclobutane-1,3'-pyrido[3',2':6,7]oxepino[4,5-b][1,4]thiazin]-2'-yl)carbamate 、 三氟乙酸 、 碳酸氢钠 、 sodium hydroxide 在 二氯甲烷 、 Sodium sulfate-III 、 silica gel 作用下， 以 水 为溶剂， 反应 0.25h， 以to afford a white solid as N-((4a′R,11b′R)-2′-amino-11b′-methyl-4′,4′-dioxido-4a′,5′,6′,11b′-tetrahydrospiro[cyclobutane-1,3′-pyrido[3′,2′:6,7]oxepino[4,5-b][1,4]thiazin]-10′-yl)-5-cyanopicolinamide (0.030 g, 0.064 mmol, 32.6% yield)的产率得到N-((4a′R,11b′R)-2′-amino-11b′-methyl-4′,4′-dioxido-4a′,5′,6′,11b′-tetrahydrospiro[cyclobutane-1,3′-pyrido[3′,2′:6,7]oxepino[4,5-b][1,4]thiazin]-10′-yl)-5-cyano-2-pyridinecarboxamide
  参考文献：
  名称：

  Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof

  摘要：

  本发明提供了一种新的化合物类别，用于调节β-秘鲁酶酶（BACE）活性。该化合物具有通式I：其中，通式I中的变量A5、A6、A8、R1、R2、R3、R7、X、Y、n和o，在此独立地定义。本发明还提供了包含该化合物的药物组合物，并提供了该化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或病况的相应用途，这是由BACE的生物活性引起的。这样的BACE介导的疾病包括，例如，阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。本发明还提供了通式II的化合物及其子式，通式III的化合物，中间体和用于制备通式I-III及其子式化合物的过程和方法。

  公开号：

  US09309263B2

文献信息

• FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF
  申请人：AMGEN INC.

  公开号：US20140213581A1

  公开（公告）日：2014-07-31

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 , X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I： 其中化学式I中的变量A 5 、A 6 、A 8 、R 1 、R 2 、R 3 、R 7 、X、Y、n和o在此独立定义。该发明还提供了包含这些化合物的药物组合物，以及这些化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的对应用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II和其亚式化合物、化学式III的化合物、中间体以及用于制备化学式I-III及其亚式化合物的化合物的制备过程和方法。
• US9309263B2
  申请人：——

  公开号：US9309263B2

  公开（公告）日：2016-04-12
• [EN] FUSED MULTICYCLIC 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE DERIVATIVES AND THEIR USE AS BETA-SECRETASE INHIBITORS<br/>[FR] DÉRIVÉS DE 3-AMINO-5,6-DIHYDRO-2H-1,4-THIAZINE MULTICYCLIQUES CONDENSÉS ET LEUR UTILISATION À TITRE D'INHIBITEURS DE BÊTA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2014120658A1

  公开（公告）日：2014-08-07

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.
• Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
  申请人：AMGEN INC.

  公开号：US09309263B2

  公开（公告）日：2016-04-12

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

  本发明提供了一种新的化合物类别，用于调节β-秘鲁酶酶（BACE）活性。该化合物具有通式I：其中，通式I中的变量A5、A6、A8、R1、R2、R3、R7、X、Y、n和o，在此独立地定义。本发明还提供了包含该化合物的药物组合物，并提供了该化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或病况的相应用途，这是由BACE的生物活性引起的。这样的BACE介导的疾病包括，例如，阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。本发明还提供了通式II的化合物及其子式，通式III的化合物，中间体和用于制备通式I-III及其子式化合物的过程和方法。